Comparison of 7-day azacitidine and 5-day decitabine for treating myelodysplastic syndrome
- 19 February 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in Annals of Hematology
- Vol. 92 (7), 889-897
- https://doi.org/10.1007/s00277-013-1702-8
Abstract
Two DNA methyltransferase inhibitors, azacitidine and decitabine, are currently approved for the treatment of myelodysplastic syndrome (MDS). Choosing between these drugs is an important practical issue. In this retrospective study, patients receiving AZA-7d (azacitidine 75 mg/m2 subcutaneously × 7 days, n = 75) or DEC-5d (decitabine 20 mg/m2 intravenously × 5 days, n = 74) were compared. The rates of hematologic response (complete response [CR]/partial response [PR]/marrow CR) were 12.0 % (AZA-7d) vs. 29.7 % (DEC-5d) (P = 0.008), and the overall response rates (CR/PR/marrow CR/hematologic improvement) were 52.0 % (AZA-7d) vs. 63.5 % (DEC-5d) (P = 0.155). Grade 3 or higher neutropenia occurred more frequently with DEC-5d (79.6 %) than with AZA-7d (72.2 %) (P = 0.040). Overall survival probabilities at 2 years were 42.1 % (AZA-7d) vs. 42.2 % (DEC-5d) (P = 0.944). Subgroup analysis revealed that AZA-7d associated with higher survival rates than DEC-5d in patients whose MDS duration exceeded 1 year or who had poor performance status. In conclusion, both AZA-7d and DEC-5d regimens were effective in treating patients with MDS. However, the two regimens differed in terms of clinical responses and toxicities. One hypomethylating regimen may be superior to the other regimen in particular subgroups.Keywords
This publication has 31 references indexed in Scilit:
- Predicting the outcome of patients with higher-risk myelodysplastic syndrome treated with hypomethylating agentsLeukemia & Lymphoma, 2012
- Azacytidine and Decitabine Induce Gene-Specific and Non-Random DNA Demethylation in Human Cancer Cell LinesPLOS ONE, 2011
- Equitoxic Doses of 5-Azacytidine and 5-Aza-2′Deoxycytidine Induce Diverse Immediate and Overlapping Heritable Changes in the TranscriptomePLOS ONE, 2010
- A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell LinesPLOS ONE, 2010
- Decitabine versus 5-azacitidine for the treatment of myelodysplastic syndrome: adjusted indirect meta-analysisHaematologica, 2009
- Mechanisms of resistance to 5-aza-2′-deoxycytidine in human cancer cell linesPublished by American Society of Hematology ,2009
- Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabineInternational Journal of Cancer, 2008
- Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemiaBlood, 2008
- DNA Methylation Inhibitor 5-Aza-2′-Deoxycytidine Induces Reversible Genome-Wide DNA Damage That Is Distinctly Influenced by DNA Methyltransferases 1 and 3BMolecular and Cellular Biology, 2008
- Epigenetic therapy of cancer: past, present and futureNature Reviews Drug Discovery, 2006